BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16690963)

  • 1. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
    Marzec M; Kasprzycka M; Lai R; Gladden AB; Wlodarski P; Tomczak E; Nowell P; Deprimo SE; Sadis S; Eck S; Schuster SJ; Diehl JA; Wasik MA
    Blood; 2006 Sep; 108(5):1744-50. PubMed ID: 16690963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
    Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
    Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.
    Wang K; Huang X; Di Liberto M; Chen-Kiang S
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):809-823. PubMed ID: 32861279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
    Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
    J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.
    Vincent-Fabert C; Fiancette R; Rouaud P; Baudet C; Truffinet V; Magnone V; Guillaudeau A; Cogné M; Dubus P; Denizot Y
    Am J Pathol; 2012 Apr; 180(4):1688-701. PubMed ID: 22326754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1.
    Jiang Z; Zhang A; Wei W; Li S
    Sci Rep; 2023 May; 13(1):8389. PubMed ID: 37225761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
    Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
    Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.
    de Vos S; Krug U; Hofmann WK; Pinkus GS; Swerdlow SH; Wachsman W; Grogan TM; Said JW; Koeffler HP
    Diagn Mol Pathol; 2003 Mar; 12(1):35-43. PubMed ID: 12605034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.
    Kim CJ; Nishi K; Isono T; Okuyama Y; Tambe Y; Okada Y; Inoue H
    Mol Carcinog; 2009 Oct; 48(10):953-64. PubMed ID: 19415719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
    Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
    Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
    Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
    Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
    Leonard JP; LaCasce AS; Smith MR; Noy A; Chirieac LR; Rodig SJ; Yu JQ; Vallabhajosula S; Schoder H; English P; Neuberg DS; Martin P; Millenson MM; Ely SA; Courtney R; Shaik N; Wilner KD; Randolph S; Van den Abbeele AD; Chen-Kiang SY; Yap JT; Shapiro GI
    Blood; 2012 May; 119(20):4597-607. PubMed ID: 22383795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ hybridization and reverse transcription-polymerase chain reaction for cyclin D1 mRNA in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues.
    Athanasiou E; Kotoula V; Hytiroglou P; Kouidou S; Kaloutsi V; Papadimitriou CS
    Mod Pathol; 2001 Feb; 14(2):62-71. PubMed ID: 11235907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
    Divakar SK; Ramana Reddy MV; Cosenza SC; Baker SJ; Perumal D; Antonelli AC; Brody J; Akula B; Parekh S; Reddy EP
    Leukemia; 2016 Jan; 30(1):86-93. PubMed ID: 26174628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism.
    Carrère N; Belaud-Rotureau MA; Dubus P; Parrens M; de Mascarel A; Merlio JP
    Haematologica; 2005 Jun; 90(6):854-6. PubMed ID: 15951302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
    Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
    Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma.
    Krieger S; Gauduchon J; Roussel M; Troussard X; Sola B
    BMC Cancer; 2006 Oct; 6():238. PubMed ID: 17022831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.